Skip to content

Keming Gao

5 papers in the library · 111 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Electroconvulsive Therapy and Ketamine Infusion in Patients with Bipolar I or II Depression: A Case Series.

Psychopharmacology Bulletin June 5, 2026 Keming Gao, Evrim Bayrak Oruc, Heather Wobbe et al.

To compare the efficacy and safety of electroconvulsive therapy (ECT) and ketamine infusion (KET-IFU) in routine care for patients with bipolar I or II depression (BPD). Electronic medical records of patients who received ECT and/or KET-IFU were used to identify patients with BPD who received both ECT and KET-IFU treatments. The change in the 16-item Quick Inventory of Depressive Symptomatology...

Racial-Ethnic Disparities in Ketamine and Esketamine Therapy for Major Depressive Disorder.

Psychiatric Services June 25, 2025 Michael Liu, Rachel Branning, Austin Lee et al. 2 citations

This study sought to investigate racial-ethnic disparities in the utilization of intravenous ketamine and intranasal esketamine therapy for major depressive disorder. The TriNetX platform was used to identify 861,179 patients diagnosed as having moderate-to-severe recurrent major depressive disorder between January 2019 and October 2024. Patients were divided into non-Hispanic White,...

DOI: 10.1176/appi.ps.20240559 (opens in new tab) Full text (opens in new tab) Esketamine Racial-ethnic disparities Unequal access Healthcare disparities +10

Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood.

Psychopharmacology Bulletin April 8, 2025 Keming Gao, Buket Koparal, Evrim Bayrak Oruc et al. 99 citations

In this case report, we present a patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder. Over a 10-year period, our case transitioned from adolescence to adulthood and received antidepressant monotherapy, adjunctive therapy with antipsychotics, lithium, or lamotrigine,...

DOI: 10.2147/ndt.S72026 (opens in new tab) Full text (opens in new tab) Esketamine Comorbidity Electroconvulsive therapy Remission +5

Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review.

Medicina (Kaunas, Lithuania) March 21, 2025 Keming Gao, Evrim Bayrak Oruc, Buket Koparal 9 citations

Objective: To narratively review currently available antidepressants and future potential antidepressants as monotherapy for the treatment of depressive disorders. Methods: Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), dopamine reuptake inhibitor (bupropion), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) were...

DOI: 10.3390/medicina61040558 (opens in new tab) Full text (opens in new tab) N-methyl-d-aspartate receptor antagonists Anti-inflammatory agents Biomarker antidepressant therapy Depressive disorders +9

Role of Electroconvulsive Therapy, Ketamine Infusion, and Deep Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Bipolar Depression: A Case Report.

Medicina (Kaunas, Lithuania) June 3, 2024 Keming Gao 1 citation

Background and Objectives: Options for treatment-resistant bipolar depression (TRBPD) are limited. Electroconvulsive therapy (ECT) has shown efficacy in TRBPD. However, the cognitive deficits and memory concerns associated with ECT are problematic for a significant number of patients. It remains unclear what the next step is for patients with TRBPD who fail ECT. Materials and Methods: In this...